Janssen Biotech’s Tremfya TV Ad ‘Misbrands’ Drug, FDA Says

Janssen Biotech’s TV advertisement for Tremfya misbrands the drug, “and makes the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act,” according to a letter from the FDA.

• FDA accuses Janssen Biotech of making misleading claims about the drug and gives the company 15 working days to address the concerns described

To contact the reporter on this story:
Airielle Lowe in Washington at alowe76@bloomberg.net

To contact the editors responsible for this story:
Kasia Klimasinska at kklimasinska@bloomberg.net

Lauren Dezenski

© 2026 Bloomberg L.P. All rights reserved. Used with permission.